Posts by: David Melamed, PhD

David Melamed, PhD

David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

October 29, 2020October 29, 2020

FDA Grants Fast Track to PC14586, Potential Therapy for Specific p53 Mutation

News

The U.S. Food and Drug Administration (FDA) has granted fast track status to PC14586, PMV Pharmaceuticals’ lead therapeutic candidate for the treatment of patients with locally advanced or metastatic ... Read more

September 17, 2020September 17, 2020

TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds

News

TTC-352, an investigational oral treatment for patients with metastatic ER-positive breast cancer that no longer responds to hormone therapy, was found to be safe and tolerable at high dose ... Read more

July 20, 2020July 20, 2020

EU Certifies Software That Assesses Short-term Breast Cancer Risk

News

ProFound AI Risk, a diagnostic tool that estimates the risk of breast cancer over a two-year period following a mammogram, has received a CE mark from the European Commission. The CE ... Read more

July 13, 2020July 13, 2020

Diet Rich in Fiber Linked to Lower Breast Cancer Risk, Pooled Data Show

News

A diet high in total fiber appears to lower the risk of breast cancer for both pre- and postmenopausal women, researchers who pooled data from 20 observational studies reported. This association ... Read more

June 8, 2020June 8, 2020

Merck to Launch Ontruzant, a Herceptin Biosimilar, in US

News

Ontruzant (trastuzumab-dttb), a biosimilar to Genentech‘s Herceptin (trastuzumab), will now be made available in the U.S. as a treatment for HER2-overexpressing breast cancers as well as for stomach cancers, according to ... Read more

February 7, 2020

Study of Treatment Aiming to Prevent Advanced Breast Cancer’s Spread to Bone Doses 1st Patient

News

GlycoMimetics announced that the first patient with advanced breast cancer has been dosed in a Phase 1b clinical trial investigating the ability of its small molecule inhibitor, GMI-1359, to stop ... Read more

February 6, 2020February 12, 2020

Keytruda-Mektovi Combo Deemed Safe in Early Triple Negative Breast Cancer Trial

News

A combination of the immune checkpoint inhibitor Keytruda (pembrolizumab) and the melanoma therapy Mektovi (binimetinib) is safe and well-tolerated by people with advanced triple negative breast cancer, preliminary findings ... Read more

January 24, 2020February 6, 2020

Phase 2 Trial of Triple Combo in Treating Advanced Breast Cancer Opening, Zymeworks Says

News

Zymeworks announced the start of a Phase 2 trial examining its experimental cancer treatment ZW25, in combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and the hormone therapy Faslodex (fulvestrant), ... Read more